SKP2 and cancer: In light of the therapeutic potential of targeting Csn5/Skp2 in cancer treatment [40], the ability of CG-12 to downregulate the expression of Csn5 and Skp2 through Sirt1 induction provides a proof-of-concept that the Csn5/Skp2 signaling axis represents a “druggable” target for this novel ERMA.